Cargando…

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim

The PI3K/mTOR/AKT pathway is an integral regulator of survival and drug resistance in multiple myeloma (MM). VS-5584 was synthesized with dual-specific and equipotent activity against mTORC1/2 and all four Class I PI3K isoforms so as to durably inhibit this pathway. We show that VS-5584 is highly ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustafa, Nurulhuda, Ting Lee, Jeannie Xue, Adina Nee, Huey Fang, Bi, Chonglei, Chung, Tae-Hoon, Hart, Stefan, Chng, Wee Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731918/ https://www.ncbi.nlm.nih.gov/pubmed/29254208 http://dx.doi.org/10.18632/oncotarget.21988

Ejemplares similares

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells
por: Anderson, Alison M., et al.
Publicado: (2017)

Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival
por: Maimouni, Sara, et al.
Publicado: (2019)

2261 Tumor suppressor RARRES1 regulates cell survival by modulating mitochondrial energetics
por: Maimouni, Sara, et al.
Publicado: (2018)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Tumor suppressor RARRES1- A novel regulator of fatty acid metabolism in epithelial cells
por: Maimouni, Sara, et al.
Publicado: (2018)

Correction: Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival
por: Maimouni, Sara, et al.
Publicado: (2021)

β→LACTAMASE-PRODUCING ANAEROBES
por: Reilly, Sheena, et al.
Publicado: (1980)

Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN
por: Oldridge, E E, et al.
Publicado: (2013)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26
por: Sahab, Ziad J., et al.
Publicado: (2010)

Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
por: Reghunathan, Renji, et al.
Publicado: (2013)

Development of a UPLC-MS/MS Method for the Quantification of VS-5584 and Its Application in Pharmacokinetic Studies in Rats
por: Zhou, Chunling, et al.
Publicado: (2020)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
por: Bi, Chonglei, et al.
Publicado: (2015)

Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
por: Xie, Zhigang, et al.
Publicado: (2011)

Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1
por: Coyle, Krysta M., et al.
Publicado: (2016)

Epigenetic Repression of RARRES1 Is Mediated by Methylation of a Proximal Promoter and a Loss of CTCF Binding
por: Peng, Zhengang, et al.
Publicado: (2012)

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma
por: Liu-Chittenden, Yi, et al.
Publicado: (2017)

VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
por: Shao, Zheren, et al.
Publicado: (2015)

BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584
por: Xu, Ming, et al.
Publicado: (2020)

PIMT is a novel and potent suppressor of endothelial activation
por: Zhang, Chen, et al.
Publicado: (2023)

RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma
por: Shyu, R-Y, et al.
Publicado: (2003)

RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation
por: Morales, Mònica, et al.
Publicado: (2014)

Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition
por: Roy, Arpita, et al.
Publicado: (2017)

RARRES3 regulates signal transduction through post-translational protein modifications
por: Hsu, Tzu-Hui, et al.
Publicado: (2015)

Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma
por: Peterfi, Lehel, et al.
Publicado: (2020)

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model
por: Siveen, Kodappully Sivaraman, et al.
Publicado: (2013)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Search for the Standard Model Higgs boson in the H → WW → ℓνℓν decay mode with 4.7 fb<sup>−1</sup> of ATLAS data at sqrt(s) = 7 TeV
por: The ATLAS collaboration
Publicado: (2012)

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
por: Shanmugam, Muthu K., et al.
Publicado: (2018)

Implementation of Space Charge Forces in BimBim
por: Gottlob, Emmanuel
Publicado: (2017)

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
por: Ning, Changwen, et al.
Publicado: (2017)

Evaluation of Bovine chemerin (RARRES2) Gene Variation on Beef Cattle Production Traits
por: Lindholm-Perry, Amanda K., et al.
Publicado: (2012)

Molecular evolution and expression profile of the chemerine encoding gene RARRES2 in baboon and chimpanzee
por: González-Alvarez, Rafael, et al.
Publicado: (2015)

IL-37 promotes cell apoptosis in cervical cancer involving Bim upregulation
por: Ouyang, Ping, et al.
Publicado: (2019)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016)

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak
por: Melarangi, T, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ro4d2ambj9299j3eiklvb6jo5p